natgillin/translations-raw huggingface dataset:
< 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10 000 do < 1/1.000), zelo redki (< 1/10.000).
Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000).
Priporočeni odmerek je ena kapsula na dan.
The recommended dose is one capsule per day.
Nenadne hude alergijske reakcije, vključno z otekanjem obraza, ustnic, jezika ali sapnika, ki lahko močno otežijo dihanje.
Sudden severe allergic reactions including swelling of the face, lip, tongue or wind pipe which can cause great difficulty in breathing.
se povečuje z vsebnostjo maščob: večja kot je vsebnost lipidov, večja je biološka uporabnost fenofibrata.
The food effect increases with the fat content: the larger the lipid content the larger the bioavailability of fenofibrate.
Koncentracija v plazmi je med neprekinjenim zdravljenjem pri katerem koli danem posamezniku stabilna.
Plasma concentrations are stable during continuous treatment in any given individual.
Povečanje vrednosti AUC∞, AUCt in Cmax znaša 111,88 %, 114,06 % in 115,28 %.
∞, AUCt, and Cmax is of 111.88%, 114.06%, and 115.28% respectively.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
4.7 Effects on ability to drive and use machines
Glejte tudi spodnje poglavje »Jemanje zdravila Pravafenix skupaj s hrano in pijačo«.
See also below section “Taking Pravafenix with food and drink”.
Zdravilo se izloča pretežno z urinom.
The drug is excreted mainly in the urine.
Pri nekaterih bolnikih je tveganje za razpad mišic večje.
The risk of muscle breakdown is greater in certain patients.
Glejte tudi poglavje 4 v tem navodilu.
Also see section 4 of this leaflet.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Majhna količina pravastatina preide v materino mleko.
A small quantity of pravastatin passes into the human breast milk.
Študije o kronični toksičnosti niso odkrile relevantnih podatkov o specifični toksičnosti fenofibrata.
Chronic toxicity studies have yielded no relevant information about specific toxicity of fenofibrate.
Okoli 50 % krožečega pravastatina se veže na plazemske beljakovine.
About 50% of circulating pravastatin is bound to plasma proteins.
Sočasno uvajanje te kombinacije lahko povzroči povečano koncentracijo obeh zdravil v plazmi.
Co-administration of this combination may cause increased plasma concentrations of both agents.
V povprečju se absorbira 34 % peroralno zaužitega odmerka, pri čemer absolutna biološka uporabnost znaša 17 %.
On average, 34% of the orally administered dose is absorbed, with an absolute bioavailability of 17%.
Pretisni omoti iz poliamida-aluminija-PVC/aluminija 2 leti
Polyamide-Aluminium-PVC/aluminium blister 2 years.
Vendar pa so rezultati v študiji večkratnega odmerka pokazali, da zdravilo ni bioekvivalentno, ker je njegova biološka uporabnost po večkratnem odmerjanju zaradi fenofibratne komponente kombinacije 20 % nižja.
However in a multiple dose study, the results showed that the product is not bioequivalent because its bioavailability after multiple dosing is a 20% lower for the fenofibrate component of the combination.
Pred zdravljenjem z zdravilom Pravafenix morate zdravniku povedati, če imate ali ste imeli kakršnekoli zdravstvene težave.
Before you take Pravafenix you should tell your doctor if you have or have had any medical problems.
Dokazano je tudi, da kombinacija fibratov in statinov sinergijsko krepi transkripcijske dejavnosti receptorjev PPARα.
Fibrates and statins in combination have also been shown to synergistically increase the transcriptional activities of PPARα receptors.
- za zvišanje ravni „dobrega“ holesterola (holesterola HDL).
- To raise the level of your ‘good' cholesterol (HDL cholesterol).
Vsebina pakiranja in dodatne informacije
Contents of the pack and other information
Študije in vitro so pokazale, da se pravastatin prenaša v hepatocite, pri čemer je vnos v druge celice znatno manjši.
In vitro studies demonstrated that pravastatin is transported into hepatocytes and with substantially less intake in other cells.
izguba spomina,
• Memory loss
Glejte tudi poglavje 4.4.
Also see section 4.4
s sečnim mehurjem (boleče ali pogosto uriniranje, potrebna po odvajanju vode ponoči), spolne motnje,
bladder problems (painful or frequent urination, having to pass water at night), sexual dysfunction.
to zdravilo, vas bo zdravnik skrbno spremljal, če imate sladkorno bolezen ali ste izpostavljeni tveganju za razvoj sladkorne bolezni.
While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes.
s statini se lahko ponovno uvede sedem dni po zadnjem odmerku fusidne kisline.
Statin therapy may be re-introduced seven days after the last dose of fusidic acid.
Zdravniku ali farmacevtu prav tako povejte, če se vam pojavi stalna oslabelost mišic.
Also tell your doctor or pharmacist if you have a muscle weakness that is constant.
Če ste med zdravljenjem omotični ali če imate zamegljen ali dvojni vid, se najprej prepričajte, da ste sposobni voziti in upravljati stroje, šele nato se tega lahko lotite.
If you experience any dizziness, blurred or double vision during treatment, make sure you are fit to drive and use machines before attempting to do so.
intravenski uporabi se 47 % odmerka izloči prek ledvic, 53 % pa biliarno in z biotransformacijo.
After intravenous administration, 47% of the dose is eliminated by the renal excretion and 53% by biliary excretion and biotransformation.
To je zelo redek neželeni učinek, ki pa je lahko nevaren.
This is a very rare reaction which can be serious if it occurs.
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
Medicines should not be disposed of via wastewater or household waste.
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Pravafenix za vse skupine pediatrične populacije pri motnjah metabolizma lipoproteinov in drugih hiperlipidemijah (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The European Medicines Agency has waived the obligation to submit the results of studies with Pravafenix in all subsets of the paediatric population in disorders of lipoprotein metabolism and other hyperlipidaemias (see section 4.2 for information on paediatric use).
PODATKI V BRAILLOVI PISAVI
INFORMATION IN BRAILLE
Naslednje trditve opisujejo farmakodinamične/farmakokinetične lastnosti posameznih zdravilnih učinkovin zdravila Pravafenix.
The following statements reflect the pharmacodynamic/pharmacokinetic properties of the individual active substances of Pravafenix.
Fenofibrat se v glavnem izloča v obliki fenofibratne kisline in njenega glukuronidnega konjugata.
Fenofibrate is mainly excreted in the form of fenofibric acid and its glucuronide conjugate.
Pri večini ljudi nenormalna raven holesterola sprva ne povzroča nobenih bolezenskih znakov.
In most people, there are no signs of cholesterol problems at first.
Pravastatin se s citokromom P450 ne presnavlja znatno, niti ni substrat ali zaviralec P-glikoproteina, ampak prej substrat za druge transportne proteine.
Pravastatin is not significantly metabolised by cytochrome P450 nor does it appear to be a substrate or an inhibitor of P-glycoprotein but rather a substrate of other transport proteins.
KAJ JE ZDRAVILO PRAVAFENIX IN ZA KAJ GA UPORABLJAMO
What pravafenix is and what it is used for
težave z ledvicami (zvišane ali znižane ravni določenih encimov v telesu, ki so vidne pri preiskavi), težave
• Kidney problems (increased or decreased levels of certain enzymes within the body seen in a test)
- ovoj kapsul: želatina, indigotin (E132), črni železov oksid (E172), titanov dioksid (E171),
- capsule shell: gelatine, indigo carmine (E132), black iron oxide (E172), titanium dioxide (E171), yellow iron oxide (E172).
Ne jemljite zdravila Pravafenix, če ste mlajši od 18 let.
Children and adolescents Do not take Pravafenix if you are under 18 years old
Fenofibrat okrepi učinek peroralnih antikoagulantov in lahko poveča tveganje za krvavitev.
Fenofibrate enhances oral anticoagulant effect and may increase risk of bleeding.
(glejte poglavje 4.3)
(see section 4.4).
občasni alopecija, fotosenzitivnostne reakcije redki
Alopecia, photosensitivity reactions
to je verjetneje, če imate visoke ravni sladkorjev in maščob v krvi, imate čezmerno telesno maso in visok krvi tlak.
This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.
ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Tecnimede Sociedade Técnico-Medicinal S.A. Tel: +351 21 041 41 00
Technimede Sociedade Técnico-Medicinal S.A. Tel: +351 21 041 41 00
ŠTEVILKA SERIJE Lot
BATCH NUMBER Lot
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Med zdravljenjem
During treatment
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
Neželeni učinki neznane pogostnosti (pogostosti ni možno oceniti iz podatkov, ki so na voljo)
Side effects of unknown frequency (frequency cannot be estimated from the available data) • Muscle weakness that is constant
Zato je treba pri teh bolnikih skrbno spremljati ledvično funkcijo in pri veliki spremembi laboratorijskih parametrov zdravljenje
The renal function of these patients must therefore be closely monitored and the treatment with fenofibrate stopped in the case of severe alteration of laboratory parameters.
Če jemljete zdravila za prebavne težave (za nevtralizacijo kisline v želodcu), vzemite zdravilo Pravafenix eno uro kasneje.
If you take indigestion remedies (used to neutralise acid in your stomach), take Pravafenix 1 hour after.
Dodatni neželeni učinki, povezani z uporabo zdravil, ki vsebujejo pravastatin ali fenofibrat, ki so jih opazili v kliničnih študijah in pri izkušnjah z zdravilom po začetku trženja in do katerih lahko pride pri uporabi zdravila Pravafenix, so našteti spodaj.
Additional adverse reactions associated with the use of medicinal products containing pravastatin or fenofibrate observed in clinical trials and postmarketing experience that may potentially occur with Pravafenix are listed below.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
s koronarno boleznijo srca, ni pa dokazov, da fibrati zmanjšajo umrljivost zaradi vseh vzrokov pri primarni ali sekundarni preventivi kardiovaskularnih bolezni.
There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease.
• razpad mišic (rabdomioliza), nekateri primeri težav s kitami, pri katerih včasih pride do zapleta
• Muscle breakdown (rhabdomyolysis), some cases of tendon problems, sometimes complicated by rupture.
so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/.
V vseh kliničnih študijah je bilo bolnikom dano navodilo, da jemljejo zdravilo Pravafenix vsak dan med večernim obrokom in da še naprej upoštevajo dietne omejitve, vpeljane pred zdravljenjem.
In all clinical trials, patients were instructed to take Pravafenix daily during the evening meal and dietary restrictions instituted before therapy should be continued.
Po peroralni uporabi se 20 % začetnega odmerka izloči z urinom, 70 % pa z blatom.
Following oral administration, 20% of the initial dose is eliminated in the urine and 70% in the faeces.
Medsebojno delovanje pravastatina in fusidne kisline lahko privede do povečanega tveganja za rabdomiolizo.
Interaction between pravastatin and fusidic acid can lead to an increased risk of rhabdomyolysis.
Poleg tega imajo fibrati lastnosti, s katerimi lahko spreminjajo velikost in gostoto delcev holesterola LDL in jih tako spreminjajo v manj aterogene.
Additionally, fibrates have the properties to modify the size and density of LDL-C particles to make them less atherogenic.
Če ste v dvomu, upoštevajte nasvet zdravnika.
If you are not sure about this, please follow your doctor's advice.
so poročali, so bili asimptomatski in niso povzročili nenormalnih izvidov laboratorijskih preiskav.
Reported cases of overdose were asymptomatic and did not give rise to abnormal laboratory tests.
Izhodiščne vrednosti kreatin-fosfokinaze so lahko uporabne tudi kot referenčne, če do zvišanja pride kasneje, med kombiniranim zdravljenjem.
The baseline CK levels may also be useful as a reference in the event of a later increase during the combination therapy.
Znižanje vrednosti AUCt, AUC∞
The decreased in AUCt, AUC∞ and Cmax
Pravastatin Pravastatin se jemlje peroralno v aktivni obliki.
Pravastatin is administered orally in the active form.
so poročali pri nekaterih statinih (isti vrsti zdravil za zniževanje holesterola kot je pravastatin)
Possible side effects reported with some statins (same type of cholesterol-lowering medicines as pravastatin)
Ena trda kapsula vsebuje 19 mg laktoze.
Each hard capsule contains 19 mg of lactose.
- Kronični ali akutni pankreatitis, razen akutnega pankreatitisa zaradi hude hipertrigliceridemije (glejte poglavje 4.4).
- Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridaemia (see section 4.4).
Ne vzemite zdravila Pravafenix, če kaj od naštetega velja za vas.
Do not take Pravafenix if any of the above applies to you.
Psihiatrične motnje motnje spanja, vključno z nespečnostjo in nočnimi morami občasni
Sleep disturbance including insomnia and nightmares
in zmanjša produkcijo apoproteina C-III.
Apoprotein C-III.
Če imate kateregakoli od teh simptomov, morate z jemanjem zdravila Pravafenix prenehati in o tem obvestiti zdravnika.
If you feel any of these symptoms you should stop taking Pravafenix and inform your doctor.
Vsebuje dve zdravilni učinkovini: pravastatin in fenofibrat.
It contains two active substances: pravastatin and fenofibrate.
Zdravilo Pravafenix vsebuje fenofibrat in pravastatin, ki imata različen način delovanja in v smislu zniževanja serumskih lipidov izkazujeta aditivno delovanje.
Pravafenix contains fenofibrate and pravastatin, which have different modes of action and show additive effects in terms of reduction of serum lipid.
Pred začetkom zdravljenja z zdravilom Pravafenix je treba izključiti sekundarne vzroke za kombinirano dislipidemijo, bolnikom pa mora biti predpisana standardna dieta za zniževanje vrednosti holesterola in trigliceridov, ki se je morajo držati tudi med zdravljenjem.
Prior to initiating Pravafenix, secondary causes of combined dyslipidaemia should be excluded and patients should be placed on a standard cholesterol and triglycerides-lowering diet which should be continued during treatment.
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred jemanjem tega zdravila posvetujte
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.
- Nosečnost in dojenje (glejte poglavje 4.6).
- Pregnancy and breast-feeding (see section 4.6).
nenormalno uriniranje (vključno z dizurijo, pogostim uriniranjem, nikturijo)
Abnormal urination (including dysuria, frequency, nocturia)
Sočasna uporaba pravastatina in ciklosporina vodi k približno štirikratnemu povečanju sistemske izpostavljenosti pravastatina.
Concomitant administration of pravastatin and ciclosporin leads to an approximately 4 fold increase in pravastatin systemic exposure.
V takih primerih je treba izmeriti vrednosti kreatin-fosfokinaze (glejte spodaj).
In such cases CK levels should be measured (see below).
Zdravilo Pravafenix je treba jemati s hrano, saj hrana zviša biološko uporabnost fenofibrata (glejte poglavji 4.2 in 5.2).
Pravafenix must be taken with food, as food enhances the bioavailability of fenofibrate (see sections 4.2 and 5.2).
Čeprav gre za manjše spremembe, je pri sočasnem jemanju pravastatina z eritromicinom ali klaritromicinom potrebna previdnost.
Although these changes were minor, caution should be exercised when associating pravastatin with erythromycin or clarithromycin.
Razpolovni časizločanja peroralno zaužitega pravastatina v plazmi je od 1,5 do 2 uri.
Plasma elimination half-life of oral pravastatin is 1.5 to 2 hours.
Žilne bolezni tromboembolija (pljučna embolija, globoka venska tromboza)*
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
(pravastatin)
(eructation)).
Pomožne snovi z znanim učinkom:
Excipient(s) with known effect:
- Pred začetkom jemanja zdravila Pravafenix morate biti na dieti za zniževanje holesterola.
- Before starting taking Pravafenix, you should be on a diet to lower your cholesterol.
Študije vpliva fenofibrata na frakcije lipoproteinov kažejo znižanje ravni holesterola LDL in VLDL.
Studies with fenofibrate on lipoprotein fractions show decreases in levels of LDL and VLDL cholesterol.
depresija,
• Depression
14 trdih kapsul 30 trdih kapsul 60 trdih kapsul 90 trdih kapsul
14 hard capsules 30 hard capsules 60 hard capsules 90 hard capsules
Farmakodinamični učinki
Pharmacodynamic effects
PRILOGA I POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
V primeru prevelikega odmerjanja je potrebno začeti simptomatsko in podporno zdravljenje.
In the event of an overdose, symptomatic and supportive measures should be employed.
Kategorije pogostnosti temeljijo na informacijah iz Povzetka glavnih značilnosti zdravila za pravastatin in fenofibrat, ki je na voljo v EU. Organski
Frequency categories are based on information available from pravastatin and fenofibrate Summary of Product characteristics available in the EU.
Pri starejših pacientih se navidezni skupni očistek fenofibratne kisline ne spremeni.
In elderly patients, the fenofibric acid apparent total plasma clearance is not modified.
Varnost sočasne uporabe pravastatina in fenofibrata so ocenjevali na podganah.
The safety of concomitant administration of pravastatin and fenofibrate was assessed in rats.
Embriotoksični učinki so dokazani v odmerkih, pri katerih se je kazala tudi toksičnost za mater (glejte poglavje 5.3).
Embryotoxic effects have been shown at doses in the range of maternal toxicity (see section 5.3).
Intersticijska pljučna bolezen
Interstitial lung disease
Vpliv hrane
Food interaction
Zaradi sočasnega dajanja se je biološka uporabnost pravastatina zmanjšala za 40 do 50 %.
Concomitant administration resulted in approximately 40 to 50% decrease in the bioavailability of pravastatin.
se vrednosti serumskih lipidov običajno naglo znižajo, če pa v treh mesecih ni ustreznega odziva, je treba zdravljenje prekiniti.
Rapid reduction of serum lipid levels usually follows Pravafenix treatment, but treatment should be discontinued if an adequate response has not been achieved within three months.
Zato je pri bolnikih, ki imajo v anamnezi pljučno embolijo, potrebna previdnost.
Therefore, caution should be exercised in patients with history of pulmonary embolism.
Holesterol je ena od maščob v krvi.
Cholesterol is one of several fats found in your blood.
Jemanje zdravila je treba zaradi možnega tveganja za plod prekiniti.
The medicine must be discontinued because of the potential risk to the foetus.
s tveganjem (glukoza na tešče od 5,6 do 6,9 mmol/l, ITM > 30 kg/m2, povišana raven trigliceridov, hipertenzija) je treba klinično in biokemično spremljati skladno z nacionalnimi smernicami.
Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI>30kg/m 2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.
Individualni učinki pravastatina in fenofibrata se med seboj dopolnjujejo.
The respective effects of pravastatin and fenofibrate are complementary.
ZA PROMET Datum prve odobritve: 14.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 April 2011
Študije na miših, podganah in kuncih niso odkrile nobenih
Studies in mice, rats and rabbits did not reveal any teratogenic effect.
ščemenje in otrplost (periferna polinevropatija).
• Tingling and numbness (peripheral polyneuropathy).
Koncentracije v plazmi so sorazmerne uporabljenim odmerkom.
The plasma concentrations are proportional to the doses administered.
To zdravilo vsebuje laktozo.
This medicinal product contains lactose.
Holesterol LDL pogosto imenujemo „slabi“ holesterol, ker se lahko kopiči v stenah arterij in tako povzroči nastanek oblog.
LDL cholesterol is often called ‘bad' cholesterol because it can build up in the walls of your arteries and form plaque.
Absorbira se hitro; najvišje serumske vrednosti so dosežene v uri do uri in pol po zaužitju.
It is rapidly absorbed; peak serum levels are achieved 1 to 1.5 hours after ingestion.
Izdelovalec
Manufacturer
Klinično pomembnega znižanja biološke uporabnosti ali terapevtskega učinka ni bilo, če je bil pravastatin vzet eno uro pred holestiraminom ali štiri ure po njem ter eno uro pred holestipolom.
There was no clinically significant decrease in bioavailability or therapeutic effect when pravastatin was administered one hour before or four hours after colestyramine or one hour before colestipol.
Sistemski očistek pravastatina je 0,81 l/h/kg, ledvični očistek pa 0,38 l/h/kg, kar kaže na tubularno sekrecijo.
The systemic clearance of pravastatin is 0.81 l/h/kg and the renal clearance is 0.38 l/h/kg indicating tubular secretion.
Očesne bolezni motnje vida (vključno z zamegljenim vidom in diplopijo)
Vision disturbance (including blurred vision and diplopia)
Glejte poglavje 4.
See section 4.
so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Opis izbranih neželenih učinkov
Description of selected adverse reactions
- Bolezen žolčnika (glejte poglavje 4.4).
- Gallbladder disease (see section 4.4).
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo navodilo.
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Klinična znaka IMNM sta trdovratna oslabelost proksimalnih mišic in povišana vrednost serumske kreatin kinaze, ki kljub ukinitvi zdravljenja s statini ne izzvenita.
IMNM is clinically characterized by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.
O izločanju fenofibrata in/ali njegovih presnovkov v materino mleko ni podatkov.
There are no data on the excretion of fenofibrate and/or its metabolites into human breast milk.
Pri merjenju je treba vrednosti kreatin-fosfokinaze razlagati skupaj z drugimi potencialnimi dejavniki, ki lahko povzročijo prehodno poškodbo mišic, npr. z naporno telesno dejavnostjo, in merjenje po potrebi ponoviti.
When measured, CK levels should be interpreted in the context of other potential factors that can cause transient muscle damage, such as strenuous exercise or muscle trauma and repeated if necessary.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali farmacevtom.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Fenofibrat lahko poveča izločanje holesterola v žolč, kar lahko vodi do holelitiaze.
Fenofibrate may increase cholesterol excretion into the bile, potentially leading to cholelithiasis.